「ポイント」・てんかん(けいれん)重積状態は, 乳幼児と高齢者に多い. ・原因は多様であり, 予後は, 基本的に原疾患に左右され, 治療に際しては複雑な要因が関与するので絶対的な方法はない. ・けいれん発作が長く続くほど止まりにくくなり, その後の脳の発達に影響する. ・わが国で2009年12月より静注用フェノバルビタール(ノーベルバール(R)), 2011年12月にフォスフェニトイン(ホストイン(R))が適応承認となったことは福音である.
[Point]: The Status Epilepticus (convulsive state) is frequently observed for the infants and the elderly. Since there is wide variety of causes, the prognosis depends on the primary disease so that there is no absolute medical treatment due to the complicated factors. If the developed convulsive seizer prolonged longer, it becomes hard to be stopped, and as a result, it may affect the brain development after then. It is the good news that two drugs, the Phenobarbital (Nobelbar®) since December 2009 and the fosphenytoin (Fostin®), have been put into the market as the approved drug labels.
・現在, ミダゾラムの静注療法はわが国で治験中(アルフレッサファーマ社)である. EUでは2011年9月に口腔内投与が認められた. わが国でも早急な開発・承認が待ち望まれる. 「はじめに」てんかん重積状態(けいれん重積〕は, 「発作がある程度の長さ以上に続くか, または短い発作でも反復しその間意識の回復がないもの」とILAE(International League Against Epilepsy)(1981)で定義されている.
・At present time, intravenous-injection treatment of midazolam is on clinical research in our country (Alfresa Pharma Corporation). In EU, its buccal administration is approved in September 2011. Urgent development and approval is also desired in our country.
[Introduction]
Status epilepticus is defined as “the condition in which a seizure continues more than some length of time or a short time seizure which repeats and the patient does not recover his/her consciousness during that time” by ILAE(International League Against Epilepsy)(1981).
